The FDA has approved Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, for adults 65 and older and those 12-64 with underlying conditions, marking the first approval under tightened FDA standards requiring more rigorous studies. In Phase 3 trials, mNEXSPIKE demonstrated a 9.3% and 13.5% higher relative efficacy compared to Moderna's original vaccine in those 12 and older and 65 and older, respectively. Moderna anticipates availability for the 2025-2026 respiratory virus season, offering an updated tool against a virus that caused over 47,000 American deaths last year.
Moderna (MRNA) has secured FDA approval for its next-generation COVID-19 vaccine, mNEXSPIKE, targeting adults 65 and older and individuals aged 12-64 with underlying conditions, a development viewed with strongly positive sentiment (0.8) for the company. This approval is notable as the first under more stringent FDA standards, which involved requirements for more extensive studies before authorizing updated shots for healthy adults under 65. The new vaccine demonstrated a 9.3% higher relative efficacy overall (12+ years) and 13.5% higher efficacy in those 65 and older compared to Moderna's original Spikevax, according to Phase 3 trial data involving approximately 11,400 participants. Moderna anticipates mNEXSPIKE's availability for the 2025-2026 respiratory virus season, aiming to address the ongoing public health threat, as evidenced by over 47,000 U.S. COVID-19 fatalities last year. However, the approval comes amidst new HHS restrictions, including no longer recommending COVID vaccines for healthy children and healthy pregnant women, which will likely refine the vaccine's target market, aligning with the overall mildly positive general sentiment and moderate market impact signals.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
